"Border Vision" plan will contribute to Canada's prosperity and create jobs

OTTAWA, April 28 /CNW/ - The following is a statement by Russell Williams, President of Canada's Research-Based Pharmaceutical Companies (Rx&D), on the "Shared Vision for Perimeter Security and Economic Competitiveness" initiative with the U.S.

"With the global economy in a still fragile state, preserving and creating good jobs and investment in cutting edge technologies and industries like life sciences should be a national priority.

"Our industry recognizes the importance of proceeding with a "Border Vision" plan which includes closer cooperation between Canada and the United States. This includes the creation of a Regulatory Cooperation Council aimed at reducing the burden of red tape and streamlining regulations to spark innovation and growth. This is welcome news to businesses large and small throughout Canada.

"Harmonizing regulations to reflect modern science and sharing best practices between Canada, the U.S. and other developed countries will reap huge benefits for Canadian patients.

"Regulatory delays don't make prescription medicines any safer and mean that patients may be denied the right to choose new treatment that will benefit them. By reducing unnecessary delays, we will be able to ensure patients have access to the right medication at the right time while also improving patient safety.

"New medicines and vaccines reduce workplace disability and save on health care costs for surgery, hospitalization and doctor visits. They also help in the fight against chronic disease which costs our health care system about $150 billion a year.

"Canada must take steps to strengthen intellectual property rights, reduce red tape and provide access to new treatments if we want to lead the world in attracting jobs and investment.

"We encourage all efforts that will bring much needed jobs and sustainable growth to Canada especially in the strategically important life sciences sector."

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.


For further information:

Mike Murphy, Communications
Telephone: 613.236.0455
E-mail: mmurphy@canadapharma.org

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890